InvestorsHub Logo
Followers 85
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: north40000 post# 154542

Saturday, 01/04/2014 10:52:56 PM

Saturday, January 04, 2014 10:52:56 PM

Post# of 346441
North40000, thanks for that Jan 2014 Publication that mentions PS targeting. Slowly but surely the advancement of Bavituximab continues.

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News